查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1531041

肝細胞生長因子(HGF) 市場（類型：III 期[正在進行]、II 期[已批准]、II 期[正在進行]、I 期和臨床前）- 全球產業分析、規模、佔有率、成長、趨勢和預測， 2024-2034

Hepatocyte Growth Factors (HGFs) Market (Type: Phase III [Ongoing], Phase II [Approved], Phase II [Ongoing], Phase I, and Preclinical) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 141 Pages | 商品交期: 2-10個工作天內

價格

肝細胞生長因子 (HGF) 市場 - 報告範圍

TMR 關於全球肝細胞生長因子(HGF) 市場的報告研究了過去以及當前的成長趨勢和機會，以獲得2024 年至2034 年預測期內市場指標的寶貴見解。 HGF) 市場的收入2018-2034年期間肝細胞生長因子（HGF）市場，考慮2024年為基準年，2034年為預測年。該報告也提供了2024年至2034年全球肝細胞生長因子（HGF）市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解肝細胞生長因子（HGF）市場。

市場概況
2023年市場價值 7030萬美元
2034 年市場價值 1.41 億美元
複合年成長率 6.5%

該報告深入研究了全球肝細胞生長因子（HGF）市場的競爭格局。全球肝細胞生長因子（HGF）市場的主要參與者已經確定，並且每位參與者都根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球肝細胞生長因子 (HGF) 市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：市場

第 4 章：市場概述

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034年市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：按類型

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按類型，2020-2034
    • 第三階段（正在進行中）
    • 第二階段（已批准）
    • 第二階段（正在進行中）
    • 第一階段
    • 臨床前
  • 市場吸引力分析：按類型

第 7 章：全球市場分析與預測：按應用分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依應用分類，2020-2034
    • 腫瘤學
    • 心血管
    • 中樞神經系統
    • 血液系統疾病
  • 市場吸引力分析：按應用

第 8 章：全球市場分析與預測：按最終用戶

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2020-2034
    • 製藥和生物技術公司
    • CMO 和 CDMO
    • 研究中心和學術機構
  • 市場吸引力分析：按最終用戶

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020-2034
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

第 14 章：中東和非洲市場分析與預測

第15章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2023）
  • 公司簡介
    • ViroMed
    • AnGes, Inc.
    • M3 Biotechnology, Inc.
    • AVEO Pharmaceuticals, Inc.
    • Molecular Partners AG
    • YooYoung Pharmaceutical Co., Ltd.
    • F-star Therapeutics Inc.
    • Galaxy Bio Tech
    • Kringle Pharma
Product Code: TMRGL86224

Hepatocyte Growth Factors (HGFs) Market - Scope of Report

TMR's report on the global hepatocyte growth factors (HGFs) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global hepatocyte growth factors (HGFs) market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hepatocyte growth factors (HGFs) market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the hepatocyte growth factors (HGFs) market.

Market Snapshot
Market Value in 2023US$ 70.3 Mn
Market Value in 2034US$ 141 Mn
CAGR6.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hepatocyte growth factors (HGFs) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hepatocyte growth factors (HGFs) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hepatocyte growth factors (HGFs) market.

The report delves into the competitive landscape of the global hepatocyte growth factors (HGFs) market. Key players operating in the global hepatocyte growth factors (HGFs) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hepatocyte growth factors (HGFs) market profiled in this report.

Key Questions Answered in Global hepatocyte growth factors (HGFs) Market Report:

  • What is the sales/revenue generated by hepatocyte growth factors (HGFs) across all regions during the forecast period?
  • What are the opportunities in the global hepatocyte growth factors (HGFs) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Hepatocyte Growth Factors (HGFs) Market - Research Objectives and Research Approach

The comprehensive report on the global hepatocyte growth factors (HGFs) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hepatocyte growth factors (HGFs) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hepatocyte growth factors (HGFs) market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Hepatocyte Growth Factors (HGFs) Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2020-2034
    • 6.3.1. Phase III (Ongoing)
    • 6.3.2. Phase II (Approved)
    • 6.3.3. Phase II (Ongoing)
    • 6.3.4. Phase I
    • 6.3.5. Preclinical
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2020-2034
    • 7.3.1. Oncology
    • 7.3.2. Cardiovascular
    • 7.3.3. Central Nervous System
    • 7.3.4. Hematological Disorders
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020-2034
    • 8.3.1. Pharmaceutical and Biotechnology Companies
    • 8.3.2. CMOs and CDMOs
    • 8.3.3. Research Centers & Academic Institutes
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Type, 2020-2034
    • 10.3.1. Phase III (Ongoing)
    • 10.3.2. Phase II (Approved)
    • 10.3.3. Phase II (Ongoing)
    • 10.3.4. Phase I
    • 10.3.5. Preclinical
  • 10.4. Market Value Forecast, by Application, 2020-2034
    • 10.4.1. Oncology
    • 10.4.2. Cardiovascular
    • 10.4.3. Central Nervous System
    • 10.4.4. Hematological Disorders
  • 10.5. Market Value Forecast, by End-user, 2020-2034
    • 10.5.1. Pharmaceutical and Biotechnology Companies
    • 10.5.2. CMOs and CDMOs
    • 10.5.3. Research Centers & Academic Institutes
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Type
    • 10.7.2. By Application
    • 10.7.3. By End-user
    • 10.7.4. By Country

11. Europe Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Type, 2020-2034
    • 11.3.1. Phase III (Ongoing)
    • 11.3.2. Phase II (Approved)
    • 11.3.3. Phase II (Ongoing)
    • 11.3.4. Phase I
    • 11.3.5. Preclinical
  • 11.4. Market Value Forecast, by Application, 2020-2034
    • 11.4.1. Oncology
    • 11.4.2. Cardiovascular
    • 11.4.3. Central Nervous System
    • 11.4.4. Hematological Disorders
  • 11.5. Market Value Forecast, by End-user, 2020-2034
    • 11.5.1. Pharmaceutical and Biotechnology Companies
    • 11.5.2. CMOs and CDMOs
    • 11.5.3. Research Centers & Academic Institutes
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Application
    • 11.7.3. By End-user
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Type, 2020-2034
    • 12.3.1. Phase III (Ongoing)
    • 12.3.2. Phase II (Approved)
    • 12.3.3. Phase II (Ongoing)
    • 12.3.4. Phase I
    • 12.3.5. Preclinical
  • 12.4. Market Value Forecast, by Application, 2020-2034
    • 12.4.1. Oncology
    • 12.4.2. Cardiovascular
    • 12.4.3. Central Nervous System
    • 12.4.4. Hematological Disorders
  • 12.5. Market Value Forecast, by End-user, 2020-2034
    • 12.5.1. Pharmaceutical and Biotechnology Companies
    • 12.5.2. CMOs and CDMOs
    • 12.5.3. Research Centers & Academic Institutes
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Application
    • 12.7.3. By End-user
    • 12.7.4. By Country/Sub-region

13. Latin America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Type, 2020-2034
    • 13.3.1. Phase III (Ongoing)
    • 13.3.2. Phase II (Approved)
    • 13.3.3. Phase II (Ongoing)
    • 13.3.4. Phase I
    • 13.3.5. Preclinical
  • 13.4. Market Value Forecast, by Application, 2020-2034
    • 13.4.1. Oncology
    • 13.4.2. Cardiovascular
    • 13.4.3. Central Nervous System
    • 13.4.4. Hematological Disorders
  • 13.5. Market Value Forecast, by End-user, 2020-2034
    • 13.5.1. Pharmaceutical and Biotechnology Companies
    • 13.5.2. CMOs and CDMOs
    • 13.5.3. Research Centers & Academic Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Application
    • 13.7.3. By End-user
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Type, 2020-2034
    • 14.3.1. Phase III (Ongoing)
    • 14.3.2. Phase II (Approved)
    • 14.3.3. Phase II (Ongoing)
    • 14.3.4. Phase I
    • 14.3.5. Preclinical
  • 14.4. Market Value Forecast, by Application, 2020-2034
    • 14.4.1. Oncology
    • 14.4.2. Cardiovascular
    • 14.4.3. Central Nervous System
    • 14.4.4. Hematological Disorders
  • 14.5. Market Value Forecast, by End-user, 2020-2034
    • 14.5.1. Pharmaceutical and Biotechnology Companies
    • 14.5.2. CMOs and CDMOs
    • 14.5.3. Research Centers & Academic Institutes
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Application
    • 14.7.3. By End-user
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. ViroMed
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. AnGes, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. M3 Biotechnology, Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. AVEO Pharmaceuticals, Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Molecular Partners AG
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. YooYoung Pharmaceutical Co., Ltd.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F-star Therapeutics Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Galaxy Bio Tech
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Kringle Pharma
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview

List of Tables

  • Table 01: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 02: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 03: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 04: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 05: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 06: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 07: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 08: North America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 09: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 11: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 12: Europe Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 13: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 15: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 16: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 17: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 19: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 20: Latin America Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 21: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Type, 2020-2034
  • Table 23: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034
  • Table 24: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Hepatocyte Growth Factors (HGFs) Market Revenue (US$ Mn), by Type, 2023
  • Figure 03: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by Type, 2023
  • Figure 04: Global Hepatocyte Growth Factors (HGFs) Market Revenue (US$ Mn), by Application, 2023
  • Figure 05: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by Application, 2023
  • Figure 06: Global Hepatocyte Growth Factors (HGFs) Market Revenue (US$ Mn), by End-user, 2023
  • Figure 07: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by End-user, 2023
  • Figure 08: Global Hepatocyte Growth Factors (HGFs) Market Value Share, by Region, 2023
  • Figure 09: Global Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 10: Global Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 11: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 13: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 14: Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 15: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 16: Global Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 22: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 23: North America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 24: North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 26:North America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 27: Europe Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 31: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 32: Europe Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 33: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 35: Europe Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 36: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 40: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 41: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 42: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 44: Asia Pacific Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 45: Latin America Hepatocyte Growth Factors (HGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 49: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 50: Latin America Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 53: Latin America Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 54: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Type, 2023 and 2034
  • Figure 58: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by Application, 2023 and 2034
  • Figure 59: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 60: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by Application, 2024-2034
  • Figure 62: Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Attractiveness Analysis, by End-user, 2024-2034